FDA Approves Therapy for Cerebral Folate Deficiency - Takeaways - MDSpire

FDA Approves Therapy for Cerebral Folate Deficiency

Decision addresses a rare neurologic disorder linked to folate transport impairment.

  • By

  • Kathryn Wighton

  • March 10, 2026

  • 2 min

Share

  • 1

    The FDA has approved Wellcovorin (leucovorin calcium) for treating cerebral folate deficiency in patients with a confirmed FOLR1 variant.

  • 2

    This approval is the first FDA-sanctioned treatment for cerebral folate deficiency linked to FOLR1 variants, a rare genetic disorder.

  • 3

    Cerebral folate deficiency can lead to severe developmental delays, movement disorders, seizures, and other neurologic complications.

  • 4

    The approval was based on a systematic review of literature demonstrating clinical benefits of Wellcovorin compared to disease natural history.

  • 5

    Adverse reactions to leucovorin may include pruritus, rash, dyspnea, and anaphylaxis, requiring immediate medical attention.

Original Source(s)

FDA Approves Therapy for Cerebral Folate Deficiency

  • by Kathryn Wighton

  • March 10, 2026

Related Content

Cortical high-threshold and low-activation characteristics in adolescent depression: a cross-age differential analysis

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Perampanel use in pediatric autoimmune encephalitis-related seizures and epilepsy: a retrospective case series